KalVista Pharmaceuticals

Sebetralstat is an oral plasma kallikrein inhibitor designed for on-demand treatment of hereditary angioedema attacks. Current standard-of-care therapies require intravenous or subcutaneous administration, which forces patients to carry injectables at all times and often delays treatment. Sebetralstat would be the first oral pill that patients can take at the first sign of an attack. Phase 3 data reported in early 2024 showed the drug met its primary endpoint of time to beginning of symptom relief, with a safety profile comparable to placebo.

KalVista originally advanced a plasma kallikrein inhibitor for diabetic macular edema, an eye disease. Phase 2 results in that indication did not demonstrate sufficient efficacy to justify further investment. The company redirected its chemistry platform to hereditary angioedema, where plasma kallikrein inhibition has a validated mechanism and the unmet need in oral delivery was clear. That decision refocused the entire pipeline on HAE, resulting in sebetralstat.

KalVista is a publicly traded company listed on Nasdaq under the ticker KALV. It funds clinical development through equity offerings and has historically attracted specialist life-science investors. Because it operates as a clinical-stage biotech with no approved products, funding is entirely tied to capital markets activity. The firm has also conducted at-the-market offerings and registered direct placements to extend its cash runway through regulatory milestones.

Ben Palleiko currently serves as CEO. He succeeded founder Andrew Crockett, who transitioned from the chief executive role and remains on the board. Crockett established the company in 2004 and drove the original scientific direction. Palleiko, who joined the firm earlier in its history, oversaw the HAE pivot and led the company through the sebetralstat Phase 3 program and preparation for a new drug application submission.

KalVista maintains R&D operations in Salisbury, United Kingdom, where the company conducts drug discovery and early-stage development. The UK site originated from the company's historical roots and continues to house a portion of the chemistry and preclinical teams. This dual-country structure gives KalVista access to UK scientific talent and certain tax incentives for research expenditure, while the Cambridge, Massachusetts headquarters manages clinical development, regulatory strategy, and corporate functions.

Following successful Phase 3 results in early 2024, KalVista prepared a new drug application for submission to the FDA. If approved, sebetralstat would be launched in the United States initially, with European filings to follow. The HAE market is estimated at over $2 billion annually, and an oral on-demand option could expand treatment rates among patients who currently delay or avoid treating attacks because of needle aversion. The company has not yet disclosed a commercialization partner.

KalVista has previously discussed a next-generation oral Factor XIIa inhibitor program for HAE prophylaxis, which would sit alongside sebetralstat as a follow-on asset. Public disclosures have focused overwhelmingly on sebetralstat, and the company has indicated that internal resources are prioritized on the regulatory submission and pre-commercial activities for the lead candidate. The broader plasma kallikrein platform chemistry remains a company asset.